Urine IgM-excretion as a prognostic marker for progression of @entity164 2 XXXX .

@entity1 @entity8 @entity6 @entity2316 @entity633 @entity177 @entity164 @entity65 @entity454
Although the clinical manifestations of @entity164 2 @entity2316 and @entity8 are similar to those in @entity164 1, the clinical course and the renal structural changes are more heterogeneous in @entity164 2 @entity6 @entity1 . Previous studies have shown that an increased urine IgM excretion in @entity1 with @entity164 1 @entity2316 was associated with poor outcome. In the present follow-up study we examine the prognostic value of baseline urine IgM excretion in @entity1 with @entity6 . METHODS: A cohort of 106 (74 male and 32 female) @entity1 with @entity164 2 @entity6 regularly attending our @entity6 out- @entity1 clinic at Skane University Hospital in Lund. They were recruited prospectively under the period between 1992 and 2004. @entity1 were followed-up until January 2009. The end point was @entity65 or @entity454 ( @entity454 ). The median follow-up time was 5 years (0.5-13 years). @entity1 were divided according to degree of @entity633 and IgM-uria. RESULTS: During follow-up time, 28 (19 male and 9 female) @entity1 died of CV events and 41 (26 male and 15 female) developed @entity454 . The risk of CV mortality was 2.4 fold, and the risk of @entity177 4.9 fold higher in @entity1 with increased urine IgM excretion compared to @entity1 with low urine IgM excretion. Stratified analysis showed that an increased urine IgM excretion was an independent predictor of @entity65 irrespective of the degree of @entity633 (HR=3.6, 95% CI: 2.1-6.0, P<0.001). In conclusion, @entity164 2 @entity2316 @entity1 with high urine IgM excretion rates carry an increased risk of @entity65 .
